KMM-1Homo sapiens (Human)Cancer cell line

Also known as: KMM1

🤖 AI SummaryBased on 16 publications

Quick Overview

Human multiple myeloma cell line with B-cell origin, used in cancer research.

Detailed Summary

KMM-1 is a human multiple myeloma cell line derived from a B-cell lineage. It is widely used in research to study the molecular mechanisms of multiple myeloma, particularly focusing on genetic abnormalities and their implications in disease progression. This cell line has been characterized for its specific chromosomal translocations and mutations, which are critical for understanding the pathogenesis of myeloma. KMM-1 is also utilized in drug sensitivity studies to evaluate the efficacy of various therapeutic agents, contributing to the development of targeted treatments. Its utility in in vitro models makes it a valuable resource for investigating the biological and genetic aspects of multiple myeloma.

Research Applications

Cancer researchGenetic studiesDrug sensitivity testing

Key Characteristics

B-cell originMultiple myeloma modelChromosomal translocations
Generated on 6/19/2025

Basic Information

Database IDCVCL_2981
SpeciesHomo sapiens (Human)

Donor Information

Age62
Age CategoryAdult
SexMale
Raceasian

Disease Information

DiseaseMultiple myeloma
LineageLymphoid
SubtypePlasma Cell Myeloma
OncoTree CodePCM

DepMap Information

Source TypeHSRRB
Source IDACH-000889_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Ser241Phe (c.722C>T)Unspecified-PubMed=23851445, PubMed=17260012
MutationSimpleNRASp.Gly13Asp (c.38G>A)Unspecified-PubMed=32014918
MutationSimpleKRASp.Val9Ile (c.25G>A)Heterozygous-Unknown

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
12,13
D13S317
9
D16S539
11
D18S51
12,14
D21S11
32.2
D3S1358
15,17
D5S818
10,11
D7S820
9,10
D8S1179
12,16
FGA
23,26
Penta D
11
Penta E
11,15
TH01
6
TPOX
9,11
vWA
16,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis.

Sirota M., Wiita A.P.

Leukemia 34:2754-2765(2020).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Whole-exon sequencing of human myeloma cell lines shows mutations related to myeloma patients at relapse with major hits in the DNA regulation and repair pathways.

Pellat-Deceunynck C.

J. Hematol. Oncol. 11:137.1-137.13(2018).

Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.

Yang H.H., Koeffler H.P.

BMC Cancer 18:940.1-940.13(2018).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.

Moreau-Aubry A., Amiot M., Pellat-Deceunynck C.

Cytometry A 87:285-288(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Responsiveness of cytogenetically discrete human myeloma cell lines to lenalidomide: lack of correlation with cereblon and interferon regulatory factor 4 expression levels.

Greenberg A.J., Walters D.K., Kumar S.K., Rajkumar S.V., Jelinek D.F.

Eur. J. Haematol. 91:504-513(2013).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.

Pellat-Deceunynck C.

Haematologica 96:574-582(2011).

An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma.

Fabris S., Lambertenghi-Deliliers G., Neri A.

BMC Med. Genomics 1:37.1-37.9(2008).

Characterization of MYC translocations in multiple myeloma cell lines.

Dib A., Gabrea A., Glebov O.K., Bergsagel P.L., Kuehl W.M.

J. Natl. Cancer Inst. Monogr. 39:25-31(2008).

Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Stewart A.K., Carpten J.D., Bergsagel P.L.

Cancer Cell 12:131-144(2007).

Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease.

Lambertenghi-Deliliers G., Bertoni F., Neri A.

Genes Chromosomes Cancer 46:226-238(2007).

Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma.

Taniwaki M., Inazawa J.

Am. J. Pathol. 165:71-81(2004).

Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma.

Kuehl W.M., Bergsagel P.L.

Blood 97:729-736(2001).

Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia.

Drexler H.G., Matsuo Y.

Leuk. Res. 24:681-703(2000).

Screening the p53 status of human cell lines using a yeast functional assay.

Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.

Mol. Carcinog. 19:243-253(1997).

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma.

Kuehl W.M.

Proc. Natl. Acad. Sci. U.S.A. 93:13931-13936(1996).

Establishment of five human myeloma cell lines.";

Yawata Y., Kimoto T.

In Vitro Cell. Dev. Biol. 25:723-729(1989).

Establishment and characterization of five human myeloma cell lines.

Ohtsuki T., Yawata Y., Namba M.

Hum. Cell 2:297-303(1989).

The leukemia-lymphoma cell line factsbook.";

Drexler H.G.

(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).

Multiple myeloma cell lines.";

Jernberg-Wiklund H., Nilsson K.

(In book chapter) Human cell culture. Vol. 3. Cancer cell lines part 3; Masters J.R.W., Palsson B.O. (eds.); pp.81-155; Kluwer Academic Publishers; New York; USA (2000).

Web Resources